These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Molecular response with triple therapy in patients with chronic myeloid leukemia]. López-Arroyo JL; Rico-Ramos HJ; Portillo-García ML Rev Med Inst Mex Seguro Soc; 2014; 52(3):262-5. PubMed ID: 24878083 [TBL] [Abstract][Full Text] [Related]
6. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F; Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584 [TBL] [Abstract][Full Text] [Related]
7. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Guilhot F; Druker B; Larson RA; Gathmann I; So C; Waltzman R; O'Brien SG Haematologica; 2009 Dec; 94(12):1669-75. PubMed ID: 19648168 [TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206 [TBL] [Abstract][Full Text] [Related]
9. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G; Blood; 2009 Apr; 113(15):3428-34. PubMed ID: 19211938 [TBL] [Abstract][Full Text] [Related]
10. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461 [TBL] [Abstract][Full Text] [Related]
11. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946 [TBL] [Abstract][Full Text] [Related]
12. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887 [TBL] [Abstract][Full Text] [Related]
13. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553 [TBL] [Abstract][Full Text] [Related]